Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA)

References

• Albrecht H, Hoffmann C, Degen O, Stoher A, Plettenberg A, Mertenskotter T, Eggers C, Stellbrink HJ (1998). Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 12: 1149–1154.
   PubMed Web of Science ®Google Scholar
• Aassari A, Cingolani A Pezzotti P, De Luca A, Murri R, Giancola ML, Larocca LM, Antinori A (2000). AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 55: 1194–1200.
   Google Scholar
• Antinori A, Giancola ML, Grisetti S, Soldani F, Alba L, Liuzzi G, Amendola A, Capobianchi M, Tozzi V, Perno CF (2002). Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1 infected patients. AIDS 16: 1867–1876.
   PubMed Web of Science ®Google Scholar
• Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, Becker JT, McArthur JC (1994). Temporal trends in the incidence of HIV-1 related neurologic dis-eases: multicenter AIDS Cohort Study, 1985–1992. Neu-rology 44: 1892–1900.
   Google Scholar
• Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Baraia J, Domingo P, Marquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Lopez-Aldeguer J, De Miguel V (2001). Clin-ical course and prognostic factors of AIDS-associated progressive multifocal leucoencephalopathy in patients treated with HAART (GESIDA). Presented at the 8th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill.
   Google Scholar
• Berger JR, Kaszovitz B, Kaszovitz B, Post JD, Dickinson G (1987). Progressive multifocal leukoencephalopathy as-sociated with human immunodeficiency virus infection. Ann Intern Med 107: 78–87.
   PubMed Web of Science ®Google Scholar
• Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998a). Pre-dictive factors for prolonged survival in acquired im-munodeficiency syndrome-associated progressive mul-tifocal leukoencephalopathy. Ann Neurol 44: 341–349.
   Google Scholar
• Berger JR, Pall L, Lanska D, Whiteman M (1998b). Progres-sive multifocal leukoencephalopathy in patients with HIV infection. J NeuroVirol 4: 59–68.
   Google Scholar
• Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB (1997). Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination ther-apy. AIDS 11: 1731–1738.
   PubMed Web of Science ®Google Scholar
• Cinque P, Casari S, Bertelli D (1998). Progressive multifocal leukoencephalopathy, HIV, and highly active antiretro-viral therapy. N Engl j Med 339: 848–849.
   Google Scholar
• Cinque P, Pierotti C, Vigano MG, Bestetti A, Fausti C, Bertelli D, Lazzarin A (2001). The good and evil of HAART in HIV-related progressive multifocal leukoen-cephalopathy. J NeuroVirol 7: 358–363.
   PubMed Web of Science ®Google Scholar
• Clifford DB (2000). Human immunodeficiency virus-associated dementia. Arch Neurol 57: 321–324.
   PubMedGoogle Scholar
• Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART im-proves prognosis in HIV-associated progressive multifo-cal leukoencephalopathy. Neurology 52: 623–625.
   PubMed Web of Science ®Google Scholar
• De Luca A, A=assari A, Cingolani A, Giancola ML, Antinori A (1998). Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretrovi-ral therapy. AIDS 12: 1937–1938.
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, A=assari A, Grisetti S, Cingolani A, Larussa D, Alba L, Murri R, Ippolito G, Cauda R, d'Arminio Monforte A, Antinori A (2001). Potent antiretroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoen-cephalopathy: extended follow up of an observational study. J NeuroVirol 7: 364–368.
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, A=assari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, d'Arminio Monforte A, Antinori A (2000). The ef-fect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoen-cephalopathy. J Infect Dis 182: 1077–1083.
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, Cingolani A, A=assari A, Gillini L, Murri R, Antinori A (1999). Clinical and virological monitoring during treatment with intrathecal cytara-bine in patients with AIDS-associated progressive mul-tifocal leukoencephalopathy. Clin Infect Dis 28: 624–628.
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Wan PC, Hanson DL, Jones JL (1999). Progres-sive multifocal leukoencephalopathy: improved sur-vival of human immunodeficiency virus-infected pa-tients in the protease inhibitor era. J Infect Dis 180: 621–625.
   PubMed Web of Science ®Google Scholar
• Gasnault J, Kousignian P, Kahraman M, Rahoiljaon J, Matheron S, Delfraissy JF, Taoufik Y (2001). Cidofovir in AIDS-associated progressive multifocal leukoen-cephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J NeuroVirol 7: 375–381.
   PubMed Web of Science ®Google Scholar
• Gasnault J, Taoufik Y, Goujaerd C, Kousignan P, Abbed K, Boue F, Dussaix E, Delfraissy JF (1999). Pro-longed survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretrovi-ral therapy. J NeuroVirol 5: 421–429.
   PubMed Web of Science ®Google Scholar
• Hall CD, Dafni U, Simpson D, Clifford D, Wetherill P, Cohen B, McArthur J, Hollander H, Yiannoutsos C, Major E, Millar L, Timpone J (1998). Failure of cy-tarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infec-tion. N Engl j Med 338: 1345–1351.
   PubMed Web of Science ®Google Scholar
• Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC (1991). Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurol-ogy 41: 1733–1736.
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL (1999). JC virus DNA load in patients with and without pro-gressive multifocal leukoencephalopathy. Neurology 52: 253–260.
   Google Scholar
• Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, Lifton M, Letvin NL (2002). Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response spe-cific for a commonly recognized JC virus epitope. J Im-munol 168: 499–504.
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Du Pasquier RA, Letvin NL (2001). JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 75: 3483–3487.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bemasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A (1999). AIDS-related opportunistic illnesses occurring after ini-tiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282: 2220–2226.
   PubMed Web of Science ®Google Scholar
• Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Donovan Post JM, Ruiz A, Bowen BC, Huang ML, Queen-Baker J, Andresen J, Kelly S, Shriver S (2002). A pilot study for progressive multifocal leukoencephalopathy in AIDS. AIDS 16: 1791–1797.
   PubMed Web of Science ®Google Scholar
• Miralles P, Berenguer J, Garcia de Viedma D, Padilla B, Cosin J, Lopez-bernaldo de Quiros JC, Munoz L, Moreno S, Bouza E (1998). Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 12: 2467–2472.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, Mc Arthur JC (2001). HIV-associated neurologic disease incidence changes: Mul-ticenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.
   Google Scholar
• Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC Jr, Visnegarwala F, Trautner BW (2002). Immune reconsti-tution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81: 213–227.
   PubMed Web of Science ®Google Scholar
• Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costigliola D (1999). Survival improvement of AIDS-related progressive multifocal leukoencephalopa-thy in the era of protease inhibitors. AIDS 13: 1881–1887.
   Google Scholar
• Weber T, Weber F, Petry H, Luke W (2001). Immune re-sponse in progressive multifocal leukoencephalopathy: an overview. J NeuroVirol 7: 311–317.
   PubMed Web of Science ®Google Scholar
• Yiannoutsos CT, Major EO, Curfrnan B, Jensen PN, Gravell M, Hou J, Clifford D, Hall CD (1999). Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syn-drome patients with biopsy-proven progressive mul-tifocal leukoencephalopathy. Ann Neurol 45: 816–820.
   PubMed Web of Science ®Google Scholar